General Gynecology · Gynecologic Oncology

Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study

Chang CP, Chen Y, Blackburn B, Abdelaziz S, Rowe K, Snyder J, Dodson M, Deshmukh V, Newman M, Stanford JB, Porucznik CA, Ose J, Fraser A, Smith K, Doherty J, Gaffney D, Hashibe M

Published May 2020 Gynecologic Oncology, 157(2), 529-535
DOI 10.1016/j.ygyno.2020.02.028 PMID 32122688 PMC PMC7869723

Abstract

Objective

While genitourinary complications during treatment for ovarian cancer are well-known, long-term adverse outcomes have not been well characterized. The number of ovarian cancer survivors has been increasing. The aim of this study was to investigate long-term adverse genitourinary outcomes in a population-based cohort.

Methods

We identified a cohort of 1270 ovarian cancer survivors diagnosed between 1996 and 2012 from the Utah Cancer Registry, and 5286 cancer-free women were matched on birth year and state from the Utah Population Database. Genitourinary disease diagnoses were identified through ICD-9 codes from electronic medical records and statewide healthcare facilities data. Cox proportional hazards models were used to estimate hazard ratios (HR) for genitourinary outcomes at 1 to <5 years and 5+ years after ovarian cancer diagnosis.

Results

Ovarian cancer survivors had increased risks for urinary system disorders (HR: 2.53, 95% CI: 2.12-3.01) and genital organ disorders (HR: 1.88, 95% CI: 1.57-2.27) between 1 and <5 years after cancer diagnosis compared to the general population cohort. Increased risks were observed for acute renal failure, chronic kidney disease, calculus of kidney, hydronephrosis, pelvic peritoneal adhesions, and pelvic organ inflammatory conditions. Increased risks of several of these diseases were observed 5+ years after cancer diagnosis.

Conclusions

Ovarian cancer survivors experience increased risks of various genitourinary diseases compared to women in the general population in the long-term. Understanding the multimorbidity trajectory among ovarian cancer survivors is important to improve clinical care after cancer treatment is completed.

Topics

By this author

Related research

General Gynecology › Gynecologic Oncology › Ovarian Cancer
Chun-Pin Chang, Yuji Chen, Brenna Blackburn, Sarah Abdelaziz, Kerry Rowe, John Snyder, Mark Dodson, Vikrant Deshmukh, Michael Newman, Joseph B Stanford, Christina A Porucznik, Jennifer Ose, Alison Fraser, Ken Smith, Jennifer Doherty, David Gaffney, Mia Hashibe
C Chang, Y Chen, B Blackburn, S Abdelaziz, K Rowe, Jack Snyder, J Snyder, M Dodson, V Deshmukh, Mike Newman, M Newman, Joe Stanford, Joey Stanford, J Stanford, C Porucznik, Jen Ose, Jenny Ose, J Ose, A Fraser, Kenneth Smith, K Smith, Jen Doherty, Jenny Doherty, J Doherty, Dave Gaffney, D Gaffney, M Hashibe
PMID 32122688 32122688 DOI 10.1016/j.ygyno.2020.02.028 10.1016/j.ygyno.2020.02.028 Chang et al. 2020, Chang 2020